The mission of the Cellular Therapy & Immunobiology Working Party is to understand and exploit the biological, including immunological, events occurring upon haematopoietic stem cell transplantation at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes.
Learn more about the CTIWP
Cellular Therapy is an emerging medical science that is today facing a unique developmental phase, well documented by the outstanding and growing numbers of clinical trials. Such an exponential growth requires proper infrastructures, cell repositories, clinical registries, technical and regulatory guidelines for appropriate cell manipulation and validation of the innovative therapeutic approaches in multicentric clinical trials.
The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of cellular manufacturing approaches designed to answer unmet medical needs.
To this aim we will actively implement:
- Retrospective and multicentric prospective transplant immunobiology studies
- Retrospective and multicentric prospective clinical trials of cell/gene therapy
- A map of European Centers active in cell manipulation and cell therapy
- A dedicated registry for cellular products and clinical trials of cell and cell-based gene therapy.
These aims will be pursued through the activity of WP subcommittees and through an active collaboration with International and European Societies of Transplantation, Cell/Gene Therapy and with major investors in the field.
Open calls to participate in a new study
The Cellular Therapy & Immunobiology Working Party is currently overseeing the following studies. Please download the survey document below.
Open until: indefinitely
Survey to evaluate and summarize advances in immune recovery after allogeneic HSCT, focusing on the recovered immune subsets likely to have the greatest impact on clinical outcomes. We would appreciate if you could answer to the following questions in appendix-I, to help us designing a proper retrospective study concerning the monitoring of post-transplant immune reconstitution.
The EBMT registry has been qualified by EMA as a suitable platform for the collection of data for post-authorisation safety surveillance and efficacy studies.
EBMT requested qualification of the cellular therapy module of the EBMT Registry as suitable for performing pharmacoepidemiological studies for regulatory purposes, concerning CAR-T cell therapy for haematological malignancies.